论文部分内容阅读
目的观察探讨酒石酸美托洛尔缓释片(倍他乐克)治疗扩张型心肌病(DCM)的临床疗效。方法 48例DCM患者随机分为对照组和治疗组,对照组24例给予常规治疗(利尿剂、ACEI或加用地高辛),治疗组24例在对照组基础上加用倍他乐克。观察治疗前后心率、血压、超声指标的变化。结果治疗组治疗后其心率、血压、超声指标均较对照组有明显改善,差异具有统计学意义(P<0.05)。结论倍他乐克可以改善扩张型心肌病患者的症状,提高生活质量,改善预后。降低再住院率与猝死。
Objective To investigate the clinical efficacy of metoprolol tartrate sustained release tablets (Betaloc) in the treatment of dilated cardiomyopathy (DCM). Methods 48 patients with DCM were randomly divided into control group and treatment group. The control group was given routine therapy (diuretic, ACEI or digoxin). The treatment group was given Betaloc on the basis of the control group. Observed before and after treatment, heart rate, blood pressure, ultrasound changes in the index. Results After treatment, the heart rate, blood pressure and ultrasound indexes of the treatment group were significantly improved compared with the control group, the difference was statistically significant (P <0.05). Conclusion Betaloc can improve the symptoms of patients with dilated cardiomyopathy, improve the quality of life and improve the prognosis. Reduce rehospitalization and sudden death.